These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1414 related items for PubMed ID: 16344100

  • 1. Management of the relapsed/refractory myeloma patient: strategies incorporating lenalidomide.
    Richardson P.
    Semin Hematol; 2005 Oct; 42(4 Suppl 4):S9-15. PubMed ID: 16344100
    [Abstract] [Full Text] [Related]

  • 2. Lenalidomide: an update on evidence from clinical trials.
    Dimopoulos MA, Terpos E.
    Blood Rev; 2010 Nov; 24 Suppl 1():S21-6. PubMed ID: 21126633
    [Abstract] [Full Text] [Related]

  • 3. Lenalidomide: new drug. Myeloma: many questions remain unanswered.
    Prescrire Int; 2008 Dec; 17(98):230-2. PubMed ID: 19422142
    [Abstract] [Full Text] [Related]

  • 4. Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma.
    Dimopoulos M, Spencer A, Attal M, Prince HM, Harousseau JL, Dmoszynska A, San Miguel J, Hellmann A, Facon T, Foà R, Corso A, Masliak Z, Olesnyckyj M, Yu Z, Patin J, Zeldis JB, Knight RD, Multiple Myeloma (010) Study Investigators.
    N Engl J Med; 2007 Nov 22; 357(21):2123-32. PubMed ID: 18032762
    [Abstract] [Full Text] [Related]

  • 5. Lenalidomide: patient management strategies.
    Hussein MA.
    Semin Hematol; 2005 Oct 22; 42(4 Suppl 4):S22-5. PubMed ID: 16344098
    [Abstract] [Full Text] [Related]

  • 6. Lenalidomide in the treatment of multiple myeloma: a review.
    Armoiry X, Aulagner G, Facon T.
    J Clin Pharm Ther; 2008 Jun 22; 33(3):219-26. PubMed ID: 18452408
    [Abstract] [Full Text] [Related]

  • 7. Combined pegylated liposomal doxorubicin and bortezomib is highly effective in patients with recurrent or refractory multiple myeloma who received prior thalidomide/lenalidomide therapy.
    Sonneveld P, Hajek R, Nagler A, Spencer A, Bladé J, Robak T, Zhuang SH, Harousseau JL, Orlowski RZ, DOXIL-MMY-3001 Study Investigators.
    Cancer; 2008 Apr 01; 112(7):1529-37. PubMed ID: 18300257
    [Abstract] [Full Text] [Related]

  • 8. Review of therapy for relapsed/refractory multiple myeloma: focus on lenalidomide.
    Mariz JM, Esteves GV.
    Curr Opin Oncol; 2012 Jan 01; 24 Suppl 2():S3-11. PubMed ID: 22245806
    [Abstract] [Full Text] [Related]

  • 9. Lenalidomide in multiple myeloma.
    Thomas SK, Richards TA, Weber DM.
    Best Pract Res Clin Haematol; 2007 Dec 01; 20(4):717-35. PubMed ID: 18070715
    [Abstract] [Full Text] [Related]

  • 10. Lenalidomide in combination with dexamethasone for the treatment of multiple myeloma after one prior therapy.
    Hazarika M, Rock E, Williams G, Dagher R, Sridhara R, Booth B, Farrell A, Justice R, Pazdur R.
    Oncologist; 2008 Oct 01; 13(10):1120-7. PubMed ID: 18922829
    [Abstract] [Full Text] [Related]

  • 11. Lenalidomide in combination with dexamethasone: effective regimen in patients with relapsed or refractory multiple myeloma complicated by renal impairment.
    Klein U, Neben K, Hielscher T, Heiss C, Ho AD, Goldschmidt H.
    Ann Hematol; 2011 Apr 01; 90(4):429-39. PubMed ID: 20857112
    [Abstract] [Full Text] [Related]

  • 12. Treatment of relapsed/refractory multiple myeloma.
    Kastritis E, Palumbo A, Dimopoulos MA.
    Semin Hematol; 2009 Apr 01; 46(2):143-57. PubMed ID: 19389498
    [Abstract] [Full Text] [Related]

  • 13. Lenalidomide in combination with dexamethasone for the treatment of relapsed or refractory multiple myeloma.
    Palumbo A, Dimopoulos M, San Miguel J, Harousseau JL, Attal M, Hussein M, Knop S, Ludwig H, von Lilienfeld-Toal M, Sonneveld P.
    Blood Rev; 2009 Mar 01; 23(2):87-93. PubMed ID: 18774632
    [Abstract] [Full Text] [Related]

  • 14. Lenalidomide in multiple myeloma.
    Richardson PG, Mitsiades C, Hideshima T, Anderson KC.
    Expert Rev Anticancer Ther; 2006 Aug 01; 6(8):1165-73. PubMed ID: 16925483
    [Abstract] [Full Text] [Related]

  • 15. Phase III clinical trial of thalidomide plus dexamethasone compared with dexamethasone alone in newly diagnosed multiple myeloma: a clinical trial coordinated by the Eastern Cooperative Oncology Group.
    Rajkumar SV, Blood E, Vesole D, Fonseca R, Greipp PR, Eastern Cooperative Oncology Group.
    J Clin Oncol; 2006 Jan 20; 24(3):431-6. PubMed ID: 16365178
    [Abstract] [Full Text] [Related]

  • 16. Long-term follow-up on overall survival from the MM-009 and MM-010 phase III trials of lenalidomide plus dexamethasone in patients with relapsed or refractory multiple myeloma.
    Dimopoulos MA, Chen C, Spencer A, Niesvizky R, Attal M, Stadtmauer EA, Petrucci MT, Yu Z, Olesnyckyj M, Zeldis JB, Knight RD, Weber DM.
    Leukemia; 2009 Nov 20; 23(11):2147-52. PubMed ID: 19626046
    [Abstract] [Full Text] [Related]

  • 17. Management of relapsed and relapsed refractory myeloma.
    Kastritis E, Mitsiades CS, Dimopoulos MA, Richardson PG.
    Hematol Oncol Clin North Am; 2007 Dec 20; 21(6):1175-215, x. PubMed ID: 17996594
    [Abstract] [Full Text] [Related]

  • 18. Perifosine plus bortezomib and dexamethasone in patients with relapsed/refractory multiple myeloma previously treated with bortezomib: results of a multicenter phase I/II trial.
    Richardson PG, Wolf J, Jakubowiak A, Zonder J, Lonial S, Irwin D, Densmore J, Krishnan A, Raje N, Bar M, Martin T, Schlossman R, Ghobrial IM, Munshi N, Laubach J, Allerton J, Hideshima T, Colson K, Poradosu E, Gardner L, Sportelli P, Anderson KC.
    J Clin Oncol; 2011 Nov 10; 29(32):4243-9. PubMed ID: 21990396
    [Abstract] [Full Text] [Related]

  • 19. Characterisation of haematological profiles and low risk of thromboembolic events with bortezomib in patients with relapsed multiple myeloma.
    Lonial S, Richardson PG, San Miguel J, Sonneveld P, Schuster MW, Bladé J, Cavenagh J, Rajkumar SV, Jakubowiak AJ, Esseltine DL, Anderson KC, Harousseau JL.
    Br J Haematol; 2008 Oct 10; 143(2):222-9. PubMed ID: 18713253
    [Abstract] [Full Text] [Related]

  • 20. Clinical efficacy of a bortezomib, cyclophosphamide, thalidomide, and dexamethasone (Vel-CTD) regimen in patients with relapsed or refractory multiple myeloma: a phase II study.
    Kim YK, Sohn SK, Lee JH, Yang DH, Moon JH, Ahn JS, Kim HJ, Lee JJ, Korean Multiple Myeloma Working Party (KMMWP).
    Ann Hematol; 2010 May 10; 89(5):475-82. PubMed ID: 19921192
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 71.